Louis Jacques On Coverage, Evidence And IDEs
This article was originally published in The Gray Sheet
In the first part of a two-part Q&A, just-departed CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
You may also be interested in...
CMS issued its final guidance on the coverage-with-evidence-development program, two years following a draft. It is explicit that local Medicare contractors can employ CED in setting coverage policies in their jurisdictions, but it is not clear that the language will encourage significant use at the local level. The guidance also revises its approach on ending CED policies compared to what was stated in the 2012 draft guidance.
Former CMS coverage chief Louis Jacques told House lawmakers that the agency’s authorities to implement coverage-with-evidence-development policies are fragmented, hindering application of the program.
In this second portion of a two-part Q&A with Louis Jacques, he talks to “The Gray Sheet” about the importance of CMS’ growing collaboration with FDA, tensions between national and local Medicare coverage policymaking and the impact of resource constraints on CMS. Jacques left his post as CMS coverage director last month.